Personalis Stock Price, News & Analysis

Personalis, Inc. (Nasdaq: PSNL) has appointed Dr. Woody Myers to its Board of Directors, enhancing its leadership with his extensive healthcare experience. Dr. Myers, previously with Blue Cross & Blue Shield of Arizona, has served on various boards and has a strong background in medicine and health policy. His addition is seen as a strategic move to bolster Personalis' commitment to precision medicine. Former director Patrick J. Balthrop has resigned, effective March 8, 2021. CEO John West expressed enthusiasm about Dr. Myers’ potential contributions to the company's vision.

Personalis, Inc. (Nasdaq: PSNL) reported record revenue of $20.2 million for Q4 2020, an 11% increase from Q4 2019. The company achieved a total of 45 customers for NeXT services and completed over 100,000 whole genomes under the VA MVP contract. Despite revenue growth, the net loss increased to $13.3 million from $6.6 million a year prior. The gross margin for Q4 was 30.1%, down from 36.2% in Q4 2019. For Q1 2021, revenues are expected around $20.3 million, with a projected net loss between $14.0 million and $15.0 million.

Personalis (Nasdaq: PSNL) and Natera (Nasdaq: NTRA) have launched a partnership to advance personalized oncology. Their collaboration combines Personalis’ NeXT tumor profiling with Natera’s Signatera ctDNA platform for monitoring treatment and assessing molecular residual disease. Natera will validate Signatera assays using Personalis' data and handle commercialization. This non-exclusive agreement aims to enhance the integration of these technologies in clinical and research applications, expanding patient access to innovative cancer monitoring solutions.

Natera, Inc. (Nasdaq: NTRA) and Personalis, Inc. (Nasdaq: PSNL) have announced a partnership aimed at enhancing personalized oncology. This non-exclusive agreement integrates Personalis' NeXT tumor profiling products with Natera's Signatera ctDNA platform for monitoring treatment and assessing molecular residual disease (MRD). Natera will validate Signatera assays using tumor and normal exome data from Personalis and take charge of commercialization. The collaboration aims to improve availability and reliability of advanced cancer diagnostics.

Personalis, Inc. (Nasdaq: PSNL) has announced participation in two upcoming investor conferences. The management team will present at the Cowen 41st Annual Healthcare Conference on March 2, 2021, at 1:30 p.m. ET, and at the Barclays Global Healthcare Conference on March 10, 2021, at 11:30 a.m. ET. Personalis specializes in advanced genomics for cancer, operating one of the largest sequencing programs and providing critical molecular data through its ImmunoID NeXT Platform.

Personalis, Inc. (Nasdaq: PSNL) announced it will release its fourth quarter 2020 financial results after the market closes on February 25, 2021. A conference call and webcast will follow at 2:00 p.m. PT / 5:00 p.m. ET to discuss these results and recent highlights. Interested parties can join via telephone or through the company's website.

Personalis, Inc. (Nasdaq: PSNL) announced the appointment of Susan Moriconi as Vice President of People and Chief Human Resources Officer. With over 20 years of experience, Moriconi previously served at Omnicell, where she significantly scaled the workforce and helped increase revenues. Her leadership is expected to enhance Personalis' culture and support its growth in the life sciences sector. CEO John West expressed confidence in her ability to foster an inclusive and high-performing environment.

Personalis, Inc. (Nasdaq: PSNL) announced its participation in the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference scheduled for February 18, 2021, at 12:00 p.m. ET. As a leader in cancer genomics and population sequencing, Personalis provides comprehensive molecular data about cancer and immune responses. The company also supports the U.S. Department of Veterans Affairs Million Veterans Program and offers the innovative ImmunoID NeXT Platform to aid biopharmaceutical customers in understanding genetic and immune system data from single samples.

Personalis, Inc. (Nasdaq: PSNL) announced a public offering of 3,950,000 shares at $38.00 each, aiming for gross proceeds of $150.1 million before expenses. The offering includes a 30-day underwriter option for an additional 592,500 shares. Morgan Stanley, BofA Securities, Citigroup, and Cowen are the joint book-running managers. The offering is backed by a shelf registration statement filed with the SEC. Personalis is recognized for its role in advanced genomics, particularly in cancer sequencing and partnering with the U.S. Department of Veterans Affairs.